ESC 365 - Switching from vitamin k antagonists to novel oral anticoagulants: predictors and outcomes.

ACVC Premium Access

Switching from vitamin k antagonists to novel oral anticoagulants: predictors and outcomes.

Session: Poster Session 2 - Cardiovascular Pharmacotherapy

Topic: Anticoagulants

Speaker: Doctor A. Marques (Almada, PT)

Event: Acute Cardiovascular Care 2019

Congress Presentation

Add to my library

About the speaker

Doctor Ana Marques

Hospital Garcia de Orta, Almada (Portugal)

4 presentations

0 follower

6 more presentations in this session

Comparing the efficacy of tranexamic acid to aprotinin in open heart surgery: A systematic review and meta-analysis

Speaker: Doctor S. Salahia (Cairo, EG)

Predictors of adverse events occurrence in patients under vitamin K antagonists

Speaker: Doctor A. Marques (Almada, PT)

A delicate balance

Speaker: Doctor M. Coutinho Cruz (Lisbon, PT)

Non-valvular atrial fibrillation (AF) and coronary artery disease with percutaneous revascularisation: safety of triple therapy with dabigatran

Speaker: Doctor M. Cano-Garcia (Malaga, ES)

Long-term mortality in TakoTsubo patients treated with different antiaggregation therapy

Speaker: Doctor E. Pogran (Vienna, AT)

Access the full session

Poster Session 2 - Cardiovascular Pharmacotherapy

Speakers: Doctor A. Marques, Doctor S. Salahia, Doctor A. Marques, Doctor M. Coutinho Cruz, Doctor M. Cano-Garcia...

About the event

Acute Cardiovascular Care 2019

2 March - 4 March 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources